Stock Events

Stock Events

Pharming Group N.V. 

€1.41
394
-€0-0.04% Wednesday 13:49

Statistics

Day High
1.41
Day Low
1.41
52W High
-
52W Low
-
Volume
3
Avg. Volume
-
Mkt Cap
912M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q2 2025
Q3 2025
Q4 2025
Next
-0.01
-0
0
0.01
Expected EPS
0.00008562800000000001
Actual EPS
N/A

Financials

-3.14%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
381.88MRevenue
-12MNet Income

Analyst Ratings

29.09Average Price Target
The highest estimate is 31.11.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHGN.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Carlisle Companies
CSL
Mkt Cap14.72B
CSL Behring competes in the plasma-derived and recombinant therapeutic products space, similar to Pharming's focus on protein replacement therapies.
Takeda Pharmaceutical
TAK
Mkt Cap52.54B
Takeda Pharmaceutical Company has a strong presence in the rare diseases market, directly competing with Pharming's portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.28B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing with Pharming's approach to treatment.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals engages in the treatment of cystic fibrosis and other rare diseases, presenting competition in the rare disease market.
AMGEN
AMGN
Mkt Cap185.74B
Amgen operates in the biotechnology field focusing on rare diseases among other areas, making it a competitor in the biopharmaceutical market.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is involved in developing and marketing products for rare diseases, among other areas, competing with Pharming.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline has a diverse portfolio including treatments for rare diseases, competing with Pharming in various therapeutic areas.
Pfizer
PFE
Mkt Cap153.59B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the pharmaceutical and biotech industry.
Sanofi
SNY
Mkt Cap112.08B
Sanofi focuses on rare diseases, multiple sclerosis, and oncology, among others, competing with Pharming in the rare disease space.

About

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Show more...
CEO
ISIN
NL0010391025
WKN
000A1H65A

Listings

F
DE
PHG.F
STU
DE
PHG.STU
MU
DE
PHGN.MU
XETRA
DE
PHGN.XETRA

0 Comments

Share your thoughts

FAQ

What is Pharming Group N.V. stock price today?▼
The current price of PHGN.XETRA is €1.41 EUR — it has decreased by -0.04% in the past 24 hours. Watch Pharming Group N.V. stock price performance more closely on the chart.
What is Pharming Group N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pharming Group N.V. stocks are traded under the ticker PHGN.XETRA.
What is Pharming Group N.V. market cap?▼
Today Pharming Group N.V. has the market capitalization of 912M
When is the next Pharming Group N.V. earnings date?▼
Pharming Group N.V. is going to release the next earnings report on May 07, 2026.
What were Pharming Group N.V. earnings last quarter?▼
PHGN.XETRA earnings for the last quarter are 0.01 EUR per share, whereas the estimation was 0 EUR resulting in a +366.67% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Pharming Group N.V. revenue for the last year?▼
Pharming Group N.V. revenue for the last year amounts to 381.88M EUR.
What is Pharming Group N.V. net income for the last year?▼
PHGN.XETRA net income for the last year is -12M EUR.
In which sector is Pharming Group N.V. located?▼
Pharming Group N.V. operates in the Other sector.
When did Pharming Group N.V. complete a stock split?▼
Pharming Group N.V. has not had any recent stock splits.